144775-06-4

Basic information

• Product Name: Thiazole, 2-[(1S)-1-azido-2-phenylethyl]-
• CAS NO: 144775-06-4
• Molecular Formula: C11H10N4S
• Molecular Weight: 230.293
• Mol File: 144775-06-4.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: Thiazole, 2-[(1S)-1-azido-2-phenylethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Thiazole, 2-[(1S)-1-azido-2-phenylethyl]-(144775-06-4)
• EPA Substance Registry System: Thiazole, 2-[(1S)-1-azido-2-phenylethyl]-(144775-06-4)

Safety Data

• Hazardous Substances Data: 144775-06-4(Hazardous Substances Data)

Upstream product

• 103-82-2 phenylacetic acid 
• 103-80-0 phenylacetyl chloride 
• 144774-99-2 2-phenyl-1-(1,3-thiazol-2-yl)ethanone 
• 95092-10-7 N-methoxy-N-methyl-2-phenylacetamide 
• 144831-03-8 (1R)-2-phenyl-1-(1,3-thiazol-2-yl)ethan-1-ol 
• 51250-91-0 bis(p-nitrophenyl) azidophosphonate 
• 6674-22-2 1,8-diazabicyclo[5.4.0]undec-7-ene 

Downstream Products

• 130199-65-4 (1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethan-1-amine 
• 120205-51-8 tert-butyl N-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]carbamate 
• 120205-54-1 tert-butyl (2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-{[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidine-1-carboxylate 
• 144775-04-2 Boc-(R)-dolaphenine 

Relevant articles and documents

Total synthesis of dolastatin 10 through ruthenium-catalyzed asymmetric hydrogenations

A total synthesis of dolastatin 10, a potent inhibitor of microtubule assembly, which displayed remarkable antineoplastic activity, is reported. Our synthetic approach was based upon ruthenium-promoted asymmetric hydrogenation of β-keto esters derived from (S)-Boc-proline and (S)-Boc-isoleucine for the construction of the two key units: (2R,3R)-Boc-dolaproine (Dap) and (3R)-Boc-dolaisoleucine (Dil).

COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER

The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention reates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.

IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug- conjugate for the treatment of cancer.